Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2026

Pfeil Alexander J, Zhang Tom, Cheng Ryan, Mattar Marissa S, Gomez Marti Juan Luis, Gili Leo, Lai Rachel, Khodos Inna, Master Rohan P, Dix Jenna-Marie, Gazzo Andrea, Arbour Kathryn C, de Stanchina Elisa, Febres-Aldana Christopher A, Ladanyi Marc, Yang Soo-Ryum, Somwar Romel

Abstract excerpt

PURPOSE: RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS, HRAS, and NRAS. Whether homologous RRAS/RRAS2 mutations are oncogenic and actionable drivers in lung cancer remains underexplored. EXPERIMENTAL DESIGN: An institutional cohort of 8,488 non-small cell lung carcinomas (NSCLC) sequenced by comprehensive targeted DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Lung Neoplasms

Share to Monomeric GTP-Binding Proteins

Share to Piperazines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41543339
DOI: 10.1158/1078-0432.CCR-25-2734
PMCID: PMC12978839

Genes

RRAS
RRAS2
F3
KRAS
HRAS
IL3
IMPACT
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.PMID 41543339Read ↗

<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Semantic proximity Read ↗

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.Semantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Semantic proximity Read ↗

Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.Semantic proximity Read ↗

Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathwaySemantic proximity Read ↗

Molecular co-alteration patterns of RICTOR-mutant metastatic lung adenocarcinomas: a single-center cohort study.Semantic proximity Read ↗

Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study.Semantic proximity Read ↗

HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature.Semantic proximity Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomasSemantic proximity Read ↗

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.